Calidi Biotherapeutics (CLDI) Receivables - Other (2022 - 2023)
Calidi Biotherapeutics (CLDI) posted quarterly Receivables - Other of $870.0 for Q1 2023, down 99.86% quarter-over-quarter from $600000.0 in Q4 2022.
Calidi Biotherapeutics (CLDI) Receivables - Other (2022 - 2023) Analysis & Trends
Calidi Biotherapeutics' Receivables - Other history runs 2 years deep, the most recent figure standing at $870.0 for Q1 2023.
- In Q1 2023, Receivables - Other changed N/A year-over-year to $870.0; the TTM figure through Mar 2023 stood at $870.0 (changed N/A YoY), while the FY2022 annual figure was $600000.0, changed N/A from the prior year.
- Receivables - Other for Q1 2023 stood at $870.0, down from $600000.0 in the prior quarter.
- The five-year high for Receivables - Other was $600000.0 in Q4 2022, with the low at $870.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 870.00 |
| Mar 31, 2023 | 870.00 |
| Dec 31, 2022 | 600,000.00 |
| Dec 31, 2022 | 600,000.00 |